Huihui Chi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Huihui Chi has a total of 235 co-authors. Here are the top co-authors by number of shared publications:
- Yutong Su
Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai
28 shared publications Jialin Teng
Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai
22 shared publicationsHonglei Liu
Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
20 shared publications- Qiongyi Hu
Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai
20 shared publications Xiaobing Cheng
Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai
20 shared publicationsYue Sun
Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
20 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1709136
Development of a predictive tool for hemophagocytic lymphohistiocytosis/macrophage activation syndrome risk in adult-onset Still’s disease
Background: Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) is one of the most common complications of adult-onset Still’s disease (AOSD), and a leading cause of organ failure and mortality in these patients. Early diagnosis and management are crucial but can be challenging. Our study aims to develop a tool for predicting the risk of HLH/MAS in AOSD patients. Methods: The study recruited AOSD patients admitted to Ruijin Hospital from May 2018 to May 2024. Clinical features and laboratory test results were collected within the first 3 days of hospitalization. Predictor variables were selected using LASSO regression, and a logistic regression model was subsequently developed to predict HLH/MAS. Model performance was assessed through calibration curves, receiver operating characteristic (ROC) curve, decision curve analysis (DCA), and bootstrap internal validation. Results: This retrospective cohort study included 190 patients with AOSD. Those who developed HLH/MAS had a higher incidence of fever and splenomegaly at admission. They also exhibited more significant reductions in blood cell counts, elevated inflammatory markers, liver dysfunction, and coagulopathy compared to patients without HLH/MAS. We developed the HLH/MAS Risk Score, which included five key predictors—body temperature, platelet count, D-dimer levels, systemic score, and initial glucocorticoid response—to assess the HLH/MAS risk in hospitalized AOSD patients. This model was visualized and demonstrated robust predictive performance, achieving an AUC of 0.86. Comparative analysis with other MAS-related models confirmed that the HLH/MAS Risk Score had competitive discriminative power. Conclusions: In this study, we developed the HLH/MAS Risk Score, a predictive tool designed to assess the risk of HLH/MAS in AOSD patients during hospitalization. The model demonstrated strong predictive performance and provides a reliable, easy-to-use tool for the early identification of patients at high risk for HLH/MAS. Further external validation is needed to confirm its clinical applicability across diverse populations.
- 31 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1709136
Open AccessDevelopment of a predictive tool for hemophagocytic lymphohistiocytosis/macrophage activation syndrome risk in adult-onset Still’s disease
Background: Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) is one of the most common complications of adult-onset Still’s disease (AOSD), and a leading cause of organ failure and mortality in these patients. Early diagnosis and management are crucial but can be challenging. Our study aims to develop a tool for predicting the risk of HLH/MAS in AOSD patients. Methods: The study recruited AOSD patients admitted to Ruijin Hospital from May 2018 to May 2024. Clinical features and laboratory test results were collected within the first 3 days of hospitalization. Predictor variables were selected using LASSO regression, and a logistic regression model was subsequently developed to predict HLH/MAS. Model performance was assessed through calibration curves, receiver operating characteristic (ROC) curve, decision curve analysis (DCA), and bootstrap internal validation. Results: This retrospective cohort study included 190 patients with AOSD. Those who developed HLH/MAS had a higher incidence of fever and splenomegaly at admission. They also exhibited more significant reductions in blood cell counts, elevated inflammatory markers, liver dysfunction, and coagulopathy compared to patients without HLH/MAS. We developed the HLH/MAS Risk Score, which included five key predictors—body temperature, platelet count, D-dimer levels, systemic score, and initial glucocorticoid response—to assess the HLH/MAS risk in hospitalized AOSD patients. This model was visualized and demonstrated robust predictive performance, achieving an AUC of 0.86. Comparative analysis with other MAS-related models confirmed that the HLH/MAS Risk Score had competitive discriminative power. Conclusions: In this study, we developed the HLH/MAS Risk Score, a predictive tool designed to assess the risk of HLH/MAS in AOSD patients during hospitalization. The model demonstrated strong predictive performance and provides a reliable, easy-to-use tool for the early identification of patients at high risk for HLH/MAS. Further external validation is needed to confirm its clinical applicability across diverse populations.
- 17 July 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (8)
Lung disease in adult-onset Still’s disease: a Chinese cohort study
Objectives: This study aimed to characterize the clinical phenotypes of adult-onset Still’s disease-related lung disease (AOSD-LD) in a Chinese cohort, and to evaluate the associations of lung disease and distinct radiographic patterns with macrophage activation syndrome (MAS) and disease relapse. Methods: In this cohort of 209 patients with AOSD, individuals were retrospectively stratified into AOSD-LD and non-lung disease groups based on radiographic findings. Clinical features associated with AOSD-LD were characterized. Multivariable Cox regression and subgroup analyses were performed to evaluate the impact of AOSD-LD on MAS and disease relapse. AOSD-LD was further categorized into acute exudative, interstitial and suspected pulmonary hypertension (PH) patterns to assess pattern-specific outcomes. Results: Lung involvement was identified in 49 (23.4%) patients, yet 69.4% were asymptomatic. Pleuritis emerged as the strongest independent risk factors of AOSD-LD (P < 0.0001). AOSD-LD was independently associated with both MAS (HR = 2.62, 95% CI: 1.38–4.96, P = 0.0041) and disease relapse (HR = 2.66, 95% CI: 1.50–4.71, P = 0.0012) in multivariable COX analysis. Radiographically, the acute exudative pattern was most prevalent, followed by interstitial and suspected PH patterns. Prognostic stratification revealed the acute exudative pattern was strongly associated with early MAS development (P = 0.0315), whereas the interstitial pattern was associated with a chronic, refractory course (P = 0.0059). Conclusion: AOSD-LD defines a severe disease phenotype and serves as a critical independent predictor for life-threatening MAS and chronic relapse. Differentiating radiographic patterns offers valuable prognostic insights, underscoring the necessity for chest CT screening and phenotype-guided management strategies in AOSD.
- 17 July 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (8)
Lung disease in adult-onset Still’s disease: a Chinese cohort study
Objectives: This study aimed to characterize the clinical phenotypes of adult-onset Still’s disease-related lung disease (AOSD-LD) in a Chinese cohort, and to evaluate the associations of lung disease and distinct radiographic patterns with macrophage activation syndrome (MAS) and disease relapse. Methods: In this cohort of 209 patients with AOSD, individuals were retrospectively stratified into AOSD-LD and non-lung disease groups based on radiographic findings. Clinical features associated with AOSD-LD were characterized. Multivariable Cox regression and subgroup analyses were performed to evaluate the impact of AOSD-LD on MAS and disease relapse. AOSD-LD was further categorized into acute exudative, interstitial and suspected pulmonary hypertension (PH) patterns to assess pattern-specific outcomes. Results: Lung involvement was identified in 49 (23.4%) patients, yet 69.4% were asymptomatic. Pleuritis emerged as the strongest independent risk factors of AOSD-LD (P < 0.0001). AOSD-LD was independently associated with both MAS (HR = 2.62, 95% CI: 1.38–4.96, P = 0.0041) and disease relapse (HR = 2.66, 95% CI: 1.50–4.71, P = 0.0012) in multivariable COX analysis. Radiographically, the acute exudative pattern was most prevalent, followed by interstitial and suspected PH patterns. Prognostic stratification revealed the acute exudative pattern was strongly associated with early MAS development (P = 0.0315), whereas the interstitial pattern was associated with a chronic, refractory course (P = 0.0059). Conclusion: AOSD-LD defines a severe disease phenotype and serves as a critical independent predictor for life-threatening MAS and chronic relapse. Differentiating radiographic patterns offers valuable prognostic insights, underscoring the necessity for chest CT screening and phenotype-guided management strategies in AOSD.
- Open Access
- 16 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5428
Deciphering Platelet Transcriptomic Profiles in Antiphospholipid Syndrome: Insights into Their Role as Immunological Players
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder driven by antiphospholipid antibodies (aPLs), primarily characterized by recurrent thrombosis and pregnancy morbidity. Transcriptomic analyses of other immune compartments have provided insights into APS pathogenesis. However, despite the central role of platelets in APS pathophysiology, their transcriptomic features remain largely unexplored. We therefore aimed to characterize the platelet transcriptomic landscape in APS and identify key immune-thrombotic pathways. RNA sequencing and bioinformatic analyses of platelets from 43 APS patients, 20 asymptomatic aPL carriers, and 20 healthy controls revealed distinct proinflammatory transcriptional reprogramming, consistent with platelets as active thrombo-inflammatory hubs. APS platelets exhibited marked activation of innate immune (Toll-like and NOD-like receptors) and neutrophil pathways, which may contribute to disease propagation through a functional platelet–neutrophil axis. A 15-gene classifier (e.g., FCER1G, MAP4K4) discriminated APS from controls with high accuracy (Area Under the Curve 0.901–0.948). The classifier also highlighted molecular differences between APS and asymptomatic aPL carriers relevant to disease progression. Network analysis suggested that anti-β2-glycoprotein I antibodies were associated with unique coagulation–immunity modules, while arterial and venous thrombosis displayed divergent cytoskeletal-energetic and lipid-signaling signatures, respectively. Together, these findings suggest that platelets in APS acquire a distinct proinflammatory phenotype and function as key immunothrombotic interfaces, supporting disease stratification and platelet-derived diagnostic strategies.
- 16 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5428
Open AccessDeciphering Platelet Transcriptomic Profiles in Antiphospholipid Syndrome: Insights into Their Role as Immunological Players
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder driven by antiphospholipid antibodies (aPLs), primarily characterized by recurrent thrombosis and pregnancy morbidity. Transcriptomic analyses of other immune compartments have provided insights into APS pathogenesis. However, despite the central role of platelets in APS pathophysiology, their transcriptomic features remain largely unexplored. We therefore aimed to characterize the platelet transcriptomic landscape in APS and identify key immune-thrombotic pathways. RNA sequencing and bioinformatic analyses of platelets from 43 APS patients, 20 asymptomatic aPL carriers, and 20 healthy controls revealed distinct proinflammatory transcriptional reprogramming, consistent with platelets as active thrombo-inflammatory hubs. APS platelets exhibited marked activation of innate immune (Toll-like and NOD-like receptors) and neutrophil pathways, which may contribute to disease propagation through a functional platelet–neutrophil axis. A 15-gene classifier (e.g., FCER1G, MAP4K4) discriminated APS from controls with high accuracy (Area Under the Curve 0.901–0.948). The classifier also highlighted molecular differences between APS and asymptomatic aPL carriers relevant to disease progression. Network analysis suggested that anti-β2-glycoprotein I antibodies were associated with unique coagulation–immunity modules, while arterial and venous thrombosis displayed divergent cytoskeletal-energetic and lipid-signaling signatures, respectively. Together, these findings suggest that platelets in APS acquire a distinct proinflammatory phenotype and function as key immunothrombotic interfaces, supporting disease stratification and platelet-derived diagnostic strategies.
- Open Access
- 3 May 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (10) , 2149-2159
A Rare RIPK3 Variant Enhances Necroptosis and Promotes Inflammation in a Still Disease–Like Autoinflammatory Syndrome
Objective: Still disease represents a prototypical polygenic systemic autoinflammatory disease, characterized by recurrent systemic inflammation and dysregulation of innate immunity. Despite extensive clinical characterization, familial clustering Still disease remains unreported. This study investigates a novel variant underlying a distinct Still disease–like autoinflammatory syndrome. Methods: Whole‐exome sequencing was performed in a three‐generation family with three affected individuals. Functional analyses were conducted to assess the impact of the receptor‐interacting protein kinase 3 ( RIPK3 ) p.Q134K variant on kinase activity, necroptosis, and inflammatory signaling. Transcriptomic profiling of peripheral blood mononuclear cells (PBMCs) and in vitro cytokine assays were used to characterize inflammatory responses. Results: A heterozygous RIPK3 p.Q134K variant was identified in all affected individuals. Functional analyses demonstrated that this variant exhibits gain‐of‐function activity, characterized by enhanced RIPK3 kinase activity and increased RIPK3 self‐association, which in turn promote mixed‐lineage kinase domain‐like protein phosphorylation and necroptosis. RNA sequencing of PBMCs from one patient revealed marked up‐regulation of NF‐κB and MAPK signaling pathways and elevated expression of interleukin‐6, and tumor necrosis factor‐α, which was effectively suppressed by pharmacologic inhibition of RIPK3. Conclusion: This study describes a familial Still disease–like autoinflammatory syndrome caused by a gain‐of‐function RIPK3 variant. Our findings establish aberrant RIPK3 activation as a driver of autoinflammation and expand the spectrum of human RIPK3‐associated diseases.
- 3 May 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (10) , 2149-2159
Open AccessA Rare RIPK3 Variant Enhances Necroptosis and Promotes Inflammation in a Still Disease–Like Autoinflammatory Syndrome
Objective: Still disease represents a prototypical polygenic systemic autoinflammatory disease, characterized by recurrent systemic inflammation and dysregulation of innate immunity. Despite extensive clinical characterization, familial clustering Still disease remains unreported. This study investigates a novel variant underlying a distinct Still disease–like autoinflammatory syndrome. Methods: Whole‐exome sequencing was performed in a three‐generation family with three affected individuals. Functional analyses were conducted to assess the impact of the receptor‐interacting protein kinase 3 ( RIPK3 ) p.Q134K variant on kinase activity, necroptosis, and inflammatory signaling. Transcriptomic profiling of peripheral blood mononuclear cells (PBMCs) and in vitro cytokine assays were used to characterize inflammatory responses. Results: A heterozygous RIPK3 p.Q134K variant was identified in all affected individuals. Functional analyses demonstrated that this variant exhibits gain‐of‐function activity, characterized by enhanced RIPK3 kinase activity and increased RIPK3 self‐association, which in turn promote mixed‐lineage kinase domain‐like protein phosphorylation and necroptosis. RNA sequencing of PBMCs from one patient revealed marked up‐regulation of NF‐κB and MAPK signaling pathways and elevated expression of interleukin‐6, and tumor necrosis factor‐α, which was effectively suppressed by pharmacologic inhibition of RIPK3. Conclusion: This study describes a familial Still disease–like autoinflammatory syndrome caused by a gain‐of‐function RIPK3 variant. Our findings establish aberrant RIPK3 activation as a driver of autoinflammation and expand the spectrum of human RIPK3‐associated diseases.
- 26 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
Benefits of adjunct plasma exchange in idiopathic inflammatory myopathy with anti-signal recognition particle antibodies: a real-world study
Objectives: The objective of this study was to compare the efficacy of adjunct plasma exchange (PE) therapy with standard therapy in idiopathic inflammatory myopathy (IIM) with anti-signal recognition particle (SRP) antibodies Methods: Anti-SRP–positive myositis patients were consecutively enrolled and followed up. Two-way ANOVA was performed to compare the pre- and post-treatment changes in myositis disease activities between the two groups. The Kaplan–Meier method was used to compare the composite end point of all-cause death and relapse after propensity score matching (PSM) and inverse probability weighting (IPW) analyses. Cox regression analyses were performed to screen long-term prognostic factors. Results: In total, 53 patients were included (35 received standard therapy, 18 received adjunct PE therapy). The PE therapy group tended to have severer muscle weakness (P = 0.027), higher levels of anti-SRP antibody titres (P = 0.001), and creatine kinase (P < 0.001), as well as higher doses of CS administration (P = 0.038). At the 4-week follow-up point, both groups achieved remarkable remission, as indicated by significant improvements in the six core set measures (CSMs), and the changes in the six CMSs were more prominent in the PE therapy group (all P < 0.001). During a median follow-up of 15 months, 26 patients reached the composite end point, and the PE therapy group had significantly better prognosis after IPW analysis (P = 0.029). In the multivariate Cox regression analyses, PE therapy [hazard ratio: 0.14 (0.03–0.57), P = 0.006] and interstitial lung disease [HR: 4.82 (1.22–19.12), P = 0.025] turned out to be independent predictors for long-term prognosis. Conclusion: Adjunct PE therapy provided quick remission and sustained benefits for IIM with anti-SRP antibodies.
- 26 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
Benefits of adjunct plasma exchange in idiopathic inflammatory myopathy with anti-signal recognition particle antibodies: a real-world study
Objectives: The objective of this study was to compare the efficacy of adjunct plasma exchange (PE) therapy with standard therapy in idiopathic inflammatory myopathy (IIM) with anti-signal recognition particle (SRP) antibodies Methods: Anti-SRP–positive myositis patients were consecutively enrolled and followed up. Two-way ANOVA was performed to compare the pre- and post-treatment changes in myositis disease activities between the two groups. The Kaplan–Meier method was used to compare the composite end point of all-cause death and relapse after propensity score matching (PSM) and inverse probability weighting (IPW) analyses. Cox regression analyses were performed to screen long-term prognostic factors. Results: In total, 53 patients were included (35 received standard therapy, 18 received adjunct PE therapy). The PE therapy group tended to have severer muscle weakness (P = 0.027), higher levels of anti-SRP antibody titres (P = 0.001), and creatine kinase (P < 0.001), as well as higher doses of CS administration (P = 0.038). At the 4-week follow-up point, both groups achieved remarkable remission, as indicated by significant improvements in the six core set measures (CSMs), and the changes in the six CMSs were more prominent in the PE therapy group (all P < 0.001). During a median follow-up of 15 months, 26 patients reached the composite end point, and the PE therapy group had significantly better prognosis after IPW analysis (P = 0.029). In the multivariate Cox regression analyses, PE therapy [hazard ratio: 0.14 (0.03–0.57), P = 0.006] and interstitial lung disease [HR: 4.82 (1.22–19.12), P = 0.025] turned out to be independent predictors for long-term prognosis. Conclusion: Adjunct PE therapy provided quick remission and sustained benefits for IIM with anti-SRP antibodies.
- 14 April 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (9) , 1975-1988
Landscape of Somatic Mutations in a Large Cohort of Chinese Patients With Immune Dysregulations
Objective: This study aims to characterize pathogenic somatic mutations in patients with autoinflammatory or autoimmune diseases lacking disease‐causing germline mutations, explore their contribution to disease pathogenesis and progression, and evaluate their implications for diagnosis and targeted therapy. Methods: We performed a systematic analysis of somatic mutations in a selected panel of 185 immune‐related genes in 2,912 patients with autoinflammatory or autoimmune diseases, recruited from 41 medical centers across China, who were previously negative for germline mutations based on whole‐exome sequencing. Results: We identified both previously reported and novel somatic mutations in genes such as UBA1 , KRAS , and NLRP3 . Pathogenic somatic mutations in TNFAIP3 were discovered first in patients with autoinflammatory diseases. The pathogenic somatic mutation detection rate was 1.35% in adults and 0.97% in children, emphasizing the importance of genetic diagnosis and novel gene discovery for somatic mutations. In addition, somatic mutations in Ras‐related genes were identified in seven patients, and 39 clonal hematopoiesis–associated mutations were identified in 36 adult patients. Moreover, myeloid cells harboring somatic mutations expanded during disease flare and reduced during remission. Disregarding the dynamic elevation of the variant allele fraction during disease progression led to therapeutic failure. Conclusion: This study delineated the genetic landscape of pathogenic somatic mutations underlying autoinflammatory and autoimmune diseases, offering valuable insights for genetic diagnosis and targeted therapies.
- 14 April 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (9) , 1975-1988
Landscape of Somatic Mutations in a Large Cohort of Chinese Patients With Immune Dysregulations
Objective: This study aims to characterize pathogenic somatic mutations in patients with autoinflammatory or autoimmune diseases lacking disease‐causing germline mutations, explore their contribution to disease pathogenesis and progression, and evaluate their implications for diagnosis and targeted therapy. Methods: We performed a systematic analysis of somatic mutations in a selected panel of 185 immune‐related genes in 2,912 patients with autoinflammatory or autoimmune diseases, recruited from 41 medical centers across China, who were previously negative for germline mutations based on whole‐exome sequencing. Results: We identified both previously reported and novel somatic mutations in genes such as UBA1 , KRAS , and NLRP3 . Pathogenic somatic mutations in TNFAIP3 were discovered first in patients with autoinflammatory diseases. The pathogenic somatic mutation detection rate was 1.35% in adults and 0.97% in children, emphasizing the importance of genetic diagnosis and novel gene discovery for somatic mutations. In addition, somatic mutations in Ras‐related genes were identified in seven patients, and 39 clonal hematopoiesis–associated mutations were identified in 36 adult patients. Moreover, myeloid cells harboring somatic mutations expanded during disease flare and reduced during remission. Disregarding the dynamic elevation of the variant allele fraction during disease progression led to therapeutic failure. Conclusion: This study delineated the genetic landscape of pathogenic somatic mutations underlying autoinflammatory and autoimmune diseases, offering valuable insights for genetic diagnosis and targeted therapies.
- Open Access
- 23 October 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Vascular uptake on 18F-FDG PET/CT predicts relapse in new-onset PMR
Objective: In this study, we utilize 18F-fluorodeoxyglucose (FDG) PET/CT to assess vascular involvement in patients with PMR, aiming to clarify its role in identifying subclinical GCA and its potential association with disease relapse. Methods: We conducted a retrospective cohort study of 80 patients diagnosed with PMR who underwent PET/CT scanning at Ruijin hospital from September 2015 to December 2023. Based on PET/CT findings, patients were divided into two groups: those with vascular involvement and those without. We compared baseline clinical characteristics, treatments and relapse rates between the two groups. Multivariate Cox regression analysis was performed to identify independent predictors of relapse. Results: In our cohort, 14 patients (14/80, 17.5%) were identified as having subclinical GCA, with 93% (13/14) exhibiting extracranial vessel involvement. Relapse rates were significantly higher in patients with subclinical GCA compared with those with isolated PMR (71% vs 29%, P = 0.003). Vascular involvement was identified as a strong predictor of relapse with a hazard ratio (HR) of 3.731 (95% CI: 1.705–8.164). Conversely, arthralgia appeared to be a protective factor against relapse with a HR of 0.325 (95% CI: 0.148–0.711). Conclusion: Our findings highlight vascular involvement as a critical predictor of relapse in PMR, underscoring the utility of 18F-FDG PET/CT in detecting subclinical GCA and predicting prognosis. Further research is needed to establish screening protocols and optimize relapse prevention strategies in this population.
- 23 October 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Open AccessVascular uptake on 18F-FDG PET/CT predicts relapse in new-onset PMR
Objective: In this study, we utilize 18F-fluorodeoxyglucose (FDG) PET/CT to assess vascular involvement in patients with PMR, aiming to clarify its role in identifying subclinical GCA and its potential association with disease relapse. Methods: We conducted a retrospective cohort study of 80 patients diagnosed with PMR who underwent PET/CT scanning at Ruijin hospital from September 2015 to December 2023. Based on PET/CT findings, patients were divided into two groups: those with vascular involvement and those without. We compared baseline clinical characteristics, treatments and relapse rates between the two groups. Multivariate Cox regression analysis was performed to identify independent predictors of relapse. Results: In our cohort, 14 patients (14/80, 17.5%) were identified as having subclinical GCA, with 93% (13/14) exhibiting extracranial vessel involvement. Relapse rates were significantly higher in patients with subclinical GCA compared with those with isolated PMR (71% vs 29%, P = 0.003). Vascular involvement was identified as a strong predictor of relapse with a hazard ratio (HR) of 3.731 (95% CI: 1.705–8.164). Conversely, arthralgia appeared to be a protective factor against relapse with a HR of 0.325 (95% CI: 0.148–0.711). Conclusion: Our findings highlight vascular involvement as a critical predictor of relapse in PMR, underscoring the utility of 18F-FDG PET/CT in detecting subclinical GCA and predicting prognosis. Further research is needed to establish screening protocols and optimize relapse prevention strategies in this population.
- Open Access
- 1 September 2025
- Published by BMJ in Lupus Science & Medicine
- Vol. 12 (2) , e001665
Glycosylation of anti-dsDNA IgG correlates with organ involvement in treatment-naïve patients with systemic lupus erythematosus
Objective: This study aimed to leverage machine learning algorithms to explore the relationship between anti-double-stranded DNA (anti-dsDNA) immunoglobulin G (IgG) glycosylation and the degree of organ involvement in patients with SLE. Methods and analysis: We enrolled 86 consecutive treatment-naïve patients with SLE positive for anti-dsDNA antibodies from the Department of Rheumatology and Immunology at Ruijin Hospital, Shanghai, between 2017 and 2019. We quantified and classified the degree of organ involvement in patients with SLE and analysed each glycoform and a combination of glycoforms of purified anti-dsDNA IgG. A random forest classifier and artificial neural network were applied to evaluate the correlation between the levels of glycoform pairs and the degree of organ involvement. Results: Pearson’s correlation analysis revealed a strong connection between the involved and uninvolved organs in patients with SLE. Random forest analysis showed that the combination of IgG1Gal and IgG3/4Bis had the highest accuracy (0.7692) and area under the curve (0.8187). In terms of predicting the degree of involvement using an artificial neural network, IgG3/4Bis and IgG1Gal showed the lowest mean squared error (0.0244). Conclusions: Our study showed the effectiveness of combining glycoforms to classify and predict the degree of SLE organ involvement. Different glycoforms were correlated with the involvement degree to various extents, and the combination of anti-dsDNA IgG3/4Bis and IgG1Gal exhibited the best correlation with organ involvement.
- 1 September 2025
- Published by BMJ in Lupus Science & Medicine
- Vol. 12 (2) , e001665
Open AccessGlycosylation of anti-dsDNA IgG correlates with organ involvement in treatment-naïve patients with systemic lupus erythematosus
Objective: This study aimed to leverage machine learning algorithms to explore the relationship between anti-double-stranded DNA (anti-dsDNA) immunoglobulin G (IgG) glycosylation and the degree of organ involvement in patients with SLE. Methods and analysis: We enrolled 86 consecutive treatment-naïve patients with SLE positive for anti-dsDNA antibodies from the Department of Rheumatology and Immunology at Ruijin Hospital, Shanghai, between 2017 and 2019. We quantified and classified the degree of organ involvement in patients with SLE and analysed each glycoform and a combination of glycoforms of purified anti-dsDNA IgG. A random forest classifier and artificial neural network were applied to evaluate the correlation between the levels of glycoform pairs and the degree of organ involvement. Results: Pearson’s correlation analysis revealed a strong connection between the involved and uninvolved organs in patients with SLE. Random forest analysis showed that the combination of IgG1Gal and IgG3/4Bis had the highest accuracy (0.7692) and area under the curve (0.8187). In terms of predicting the degree of involvement using an artificial neural network, IgG3/4Bis and IgG1Gal showed the lowest mean squared error (0.0244). Conclusions: Our study showed the effectiveness of combining glycoforms to classify and predict the degree of SLE organ involvement. Different glycoforms were correlated with the involvement degree to various extents, and the combination of anti-dsDNA IgG3/4Bis and IgG1Gal exhibited the best correlation with organ involvement.
- Top Cited PapersOpen Access
- 31 July 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (5) , 612-627
Ruxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndrome
Macrophage activation syndrome (MAS) is believed to be caused by inappropriate proliferation and activation of the mononuclear phagocytic system. Adult-onset Still disease (AOSD) is characterized by neutrophil activation and a cytokine storm, which can lead to the severe and potentially life-threatening complication of MAS. RNA sequencing revealed that neutrophils may play a distinct role and enhance the innate immunity of patients with AOSD with MAS (AOSD-MAS). In the CpG-induced secondary hemophagocytic lymphohistiocytosis (HLH) model, the depletion of neutrophils significantly reduced cytokine levels with effects comparable with monocyte depletion. Significant enrichment was observed in the type I/II interferon and JAK-STAT pathways in neutrophils from patients with AOSD-MAS. Treatment of 10 patients with refractory AOSD-MAS with ruxolitinib led to the resolution of inflammatory parameters and clinical symptoms. RNA sequencing and ex vivo assays confirmed that ruxolitinib suppressed aberrant NETosis and STAT3/STAT5 signaling. In vivo, PAD4 knockout further confirmed the pathogenic role of NETosis in a secondary HLH model. Moreover, the selective inhibition of STAT3 or STAT5 alleviated systemic inflammation. Ten functional variants were identified in genes related to the JAK-STAT pathway, however, their clinical relevance requires further validation. These findings suggest that ruxolitinib has the potential to facilitate disease remission in patients with refractory AOSD-MAS by broadly inhibiting JAK-STAT signaling and modulating neutrophil activation and NETosis.
- 31 July 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (5) , 612-627
Top Cited PapersOpen AccessRuxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndrome
Macrophage activation syndrome (MAS) is believed to be caused by inappropriate proliferation and activation of the mononuclear phagocytic system. Adult-onset Still disease (AOSD) is characterized by neutrophil activation and a cytokine storm, which can lead to the severe and potentially life-threatening complication of MAS. RNA sequencing revealed that neutrophils may play a distinct role and enhance the innate immunity of patients with AOSD with MAS (AOSD-MAS). In the CpG-induced secondary hemophagocytic lymphohistiocytosis (HLH) model, the depletion of neutrophils significantly reduced cytokine levels with effects comparable with monocyte depletion. Significant enrichment was observed in the type I/II interferon and JAK-STAT pathways in neutrophils from patients with AOSD-MAS. Treatment of 10 patients with refractory AOSD-MAS with ruxolitinib led to the resolution of inflammatory parameters and clinical symptoms. RNA sequencing and ex vivo assays confirmed that ruxolitinib suppressed aberrant NETosis and STAT3/STAT5 signaling. In vivo, PAD4 knockout further confirmed the pathogenic role of NETosis in a secondary HLH model. Moreover, the selective inhibition of STAT3 or STAT5 alleviated systemic inflammation. Ten functional variants were identified in genes related to the JAK-STAT pathway, however, their clinical relevance requires further validation. These findings suggest that ruxolitinib has the potential to facilitate disease remission in patients with refractory AOSD-MAS by broadly inhibiting JAK-STAT signaling and modulating neutrophil activation and NETosis.
- Open Access
- 6 January 2024
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 11 (1) , 201-212
Characteristics of COVID-19 and Impact of Disease Activity in Patients with Adult-Onset Still’s Disease
Introduction This study aimed to characterize the morbidity, hospitalization, and mortality rates among patients with adult-onset Still’s disease (AOSD) affected by coronavirus disease 2019 (COVID-19) and explore the impact of COVID-19 on the disease activity of AOSD. Methods Data on the clinical and demographic characteristics, COVID-19-related symptoms, and outcomes were retrospectively collected. Patients were stratified according to COVID-19 severity and associations between risk factors and outcomes were analyzed using multivariate logistic regression. The disease activity of patients with AOSD flares after COVID-19 was described. Results A total of 188 patients with AOSD were followed up, of whom 75.5% (n = 142) had a confirmed or highly suspected COVID-19. Patients on medium or high-dose oral glucocorticoids or Janus kinase (JAK) inhibitors were at increased risk of developing moderate to severe COVID-19. Six patients suffered flares of AOSD following COVID-19 in a short period; however, the relapse rate was not statistically increased compared with patients without COVID-19. Conclusion Patients with AOSD receiving medium or high-dose glucocorticoid therapy or JAK inhibitors had worse COVID-19 outcomes. Further work is needed to explore risk factors affecting COVID-19 outcomes and the impact of COVID-19 on disease activity in AOSD.
- 6 January 2024
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 11 (1) , 201-212
Open AccessCharacteristics of COVID-19 and Impact of Disease Activity in Patients with Adult-Onset Still’s Disease
Introduction This study aimed to characterize the morbidity, hospitalization, and mortality rates among patients with adult-onset Still’s disease (AOSD) affected by coronavirus disease 2019 (COVID-19) and explore the impact of COVID-19 on the disease activity of AOSD. Methods Data on the clinical and demographic characteristics, COVID-19-related symptoms, and outcomes were retrospectively collected. Patients were stratified according to COVID-19 severity and associations between risk factors and outcomes were analyzed using multivariate logistic regression. The disease activity of patients with AOSD flares after COVID-19 was described. Results A total of 188 patients with AOSD were followed up, of whom 75.5% (n = 142) had a confirmed or highly suspected COVID-19. Patients on medium or high-dose oral glucocorticoids or Janus kinase (JAK) inhibitors were at increased risk of developing moderate to severe COVID-19. Six patients suffered flares of AOSD following COVID-19 in a short period; however, the relapse rate was not statistically increased compared with patients without COVID-19. Conclusion Patients with AOSD receiving medium or high-dose glucocorticoid therapy or JAK inhibitors had worse COVID-19 outcomes. Further work is needed to explore risk factors affecting COVID-19 outcomes and the impact of COVID-19 on disease activity in AOSD.